[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].

Abstract

Imatinib mesylate (imatinib) has shown significant effects in patients with chronic myelogenous leukemia. However, hematological toxicity often occurs and requires dosage reduction or discontinuation of imatinib treatment. A patient with chronic myelogenous leukemia in the blastic crisis received granulocyte-colony stimulating factor (G-CSF) simultaneously with imatinib. The patient was continuously treated with imatinib and G-CSF and achieved remission without any severe infection or neutropenia. There are a few reports on the efficacy of combined therapy with G-CSF and imatinib; however, the results in our case are rare suggesting that the use of G-CSF is effective for preventing severe infection. G-CSF enables continuous treatment with high-dose imatinib.

• Authors: Rena Morita, Satoshi Hashino, Susumu Sogabe, Masayoshi Dazai, Masahiro Onozawa, Koh Izumiyama, Takeshi Kondo, Syuichi Ota, Sumiko Kobayashi, Masahiro Imamura, Masahiro Asaka
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 45 Issue 10 Pg. 1105-10 (Oct 2004) ISSN: 0485-1439 [Print] Japan
• PMID: 15553045 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Benzamides
• Piperazines
• Pyrimidines
• Granulocyte Colony-Stimulating Factor
• Imatinib Mesylate

Topics

• Bacterial Infections (prevention & control)
• Benzamides
• Blast Crisis (drug therapy)
• Drug Therapy, Combination
• Fatal Outcome
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
• Male
• Middle Aged
• Neutropenia (prevention & control)
• Piperazines (administration & dosage, adverse effects)
• Pyrimidines (administration & dosage, adverse effects)
• Remission Induction